JANX:NASDAQ, Janux Therapeutics, Inc.

JANX stock overview

Janux Therapeutics, Inc. (JANX:NASDAQ) closed at $17.14 on October 14, 2026, down 0.23% on the day. The stock trades 51.5% below its 52-week high of $35.34 and 41.4% above its 52-week low of $12.12. Over the past year, it lost 33.2%. Janux Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price: $17.14
Day change: -0.23%
Volume: 211,885
Average volume: 849,614
Market cap: 1B+
52-week range: $12.12 – $35.34
50-day average: $17.41
200-day average: $15.12

Performance

5D	1M	3M	6M	1Y
-6.58%	-0.75%	+8.46%	+8.60%	-33.23%

Price action over the past year

In 252 trading sessions since October 13, 2025, JANX closed higher on 125 days (50%). Its best day was January 22, 2026 (+14.09%) and its worst was December 2, 2025 (-53.34%). The stock moved 10% or more in a single session 3 times.

Recent signals

Oct 13, 2026: Trading sideways between $16.25 and $18.50 over 30 days (Sideways scanner)
Sep 27, 2026: News catalyst: Biotech (News Catalysts scanner)

JANX news

Oct 13, 2026: Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
Oct 10, 2026: Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run
Sep 30, 2026: Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Sep 29, 2026: Is Janux's Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
Sep 27, 2026: Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
Sep 16, 2026: The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Sep 15, 2026: 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Sep 14, 2026: Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

About Janux Therapeutics, Inc.

Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

Find more stocks like JANX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.